Epidermophyton Allergy Shots: This Is a Skin Infection, Not an Inhaled Allergen
Epidermophyton floccosum is a dermatophyte — a skin-infecting keratinophilic fungus responsible for tinea corporis (ringworm), tinea cruris (jock itch), tinea pedis (athlete's foot), and onychomycosis. This is not a classical respiratory aeroallergen, and SCIT is not a standard or evidence-based therapy. The established treatment is antifungal medication — topical azoles or terbinafine for skin disease, systemic terbinafine or itraconazole for nail infection.
Epidermophyton Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to epidermophyton — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of epidermophyton allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of epidermophyton immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of epidermophyton extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for epidermophyton allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing epidermophyton extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription epidermophyton immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat epidermophyton allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Epidermophyton?
The biology, taxonomy, and clinical fingerprint of Epidermophyton — the foundation of how SCIT targets it.
Epidermophyton floccosum macroconidia have characteristic smooth-walled, club-shaped 'banana cluster' morphology. They are not aeroallergens — infection occurs via skin contact, not inhalation.
- Scientific name
- Epidermophyton floccosum (Harz) Langeron & Miloch.
- Family
- Arthrodermataceae (Onygenales, Eurotiomycetes, Ascomycota)Dermatophyte fungi family
- Type
- Anthropophilic dermatophyte — skin, hair, and nail infecting fungus; NOT a respiratory aeroallergen
- Native to
- Cosmopolitan — global distribution in human skin environments
- Allergen proteins
- No WHO/IUIS-registered Epidermophyton floccosum allergen as of 2024Trichophyton has Tri r 2 and Tri r 4 as related dermatophyte allergens but Epidermophyton-specific IgE proteins are not characterizedDelayed-type hypersensitivity to dermatophyte mannan and cell wall antigens is common but distinct from IgE allergy
- Particle size
- Macroconidia 20–40 × 6–12 µm (smooth-walled, club-shaped, 'banana cluster' — not significantly aerosolized)
- Avoidance difficulty
- Manageable
How Epidermophyton Allergy Presents
Symptoms by body system — useful for distinguishing Epidermophyton sensitivity from overlapping allergies and infections.
Dermal (Primary — infection, not allergy)
- Tinea corporis (ringworm) — circular scaly, itchy patches on skin
- Tinea cruris (jock itch) — erythematous, itchy rash in groin/inner thigh area
- Tinea pedis (athlete's foot) — interdigital scaling, maceration, or vesicular eruption on feet
- Onychomycosis — thickened, discolored, brittle fingernails or toenails
Respiratory (Rare — niche IgE context only)
- Epidermophyton is NOT a respiratory aeroallergen — respiratory symptoms are not a feature of typical E. floccosum infection
- Rare case reports of asthma in atopic patients with high-titer IgE to dermatophyte antigens — not established clinical practice
- If respiratory symptoms coexist, workup should focus on inhaled aeroallergens, not the dermatophyte
Ocular (Not applicable to typical infection)
- No established ocular disease from Epidermophyton floccosum
- Any ocular allergy symptoms should be attributed to known inhalant allergens — not to this dermatophyte
- Conjunctivitis is not a reported feature of tinea infections
Systemic
- 'Id reactions' (dermatophytid) — vesicular or eczematous eruptions at body sites distant from the primary infection, mediated by delayed-type hypersensitivity (Hay 1986 Br J Dermatol)
- Atopic dermatitis flares associated with skin dermatophyte colonization
- Tinea pedis affects up to 15–25% of adults globally (Havlickova 2008 Mycoses)
When I see Epidermophyton on an allergy panel, the first question is: why was this ordered? For most patients this is an incidental inclusion in a comprehensive panel. The relevant conversation is whether they have active tinea and need an antifungal — not whether allergy shots are indicated. SCIT for Epidermophyton is not supported by any guideline, and redirecting patients toward dermatologic care is the right clinical move.
Where Epidermophyton Triggers Year-Round
Epidermophyton is a perennial trigger — exposure is constant for sensitized patients. Geographic intensity still varies by climate.
12-Month Intensity
Year-roundDermatophyte infections are perennial — slightly more common in warm, humid conditions (summer) when sweating increases skin maceration· Year-round — infection is determined by skin contact exposure, not season
US Exposure Map
0 high-intensity statesWhat Epidermophyton Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Epidermophyton cross-reacts with Trichophyton species (the more common dermatophyte genus) via shared fungal cell wall antigens; both cause delayed-type hypersensitivity reactions in infected individuals. True IgE-mediated cross-reactivity is not well characterized.
Closest relative — both Arthrodermataceae dermatophytes; shared delayed-type hypersensitivity antigens
Is SCIT Right for Your Epidermophyton Allergy?
If you are seeing Epidermophyton on a test result and wondering about allergy shots, these questions will clarify whether you have a skin infection (most likely) or a rare IgE-mediated condition requiring specialist evaluation.
What symptoms are you experiencing related to Epidermophyton?
The Epidermophyton SCIT Protocol
SCIT is NOT indicated for Epidermophyton floccosum. The established treatment for dermatophyte infection is antifungal pharmacotherapy, not immunotherapy. This section describes the antifungal treatment approach as the relevant clinical pathway.
Topical azoles (clotrimazole 1%, miconazole 2%, ketoconazole 2%) or terbinafine 1% cream are first-line for limited skin tinea. Application continues for 1–2 weeks beyond clinical resolution to prevent recurrence. Tinea pedis may require 4–6 weeks of topical treatment given the more extensive and recurrent nature of foot involvement.
Oral terbinafine 250 mg daily for 6 weeks (fingernails) or 12 weeks (toenails) is the evidence-based treatment for onychomycosis (Gupta 2018 JEADV). Itraconazole pulse therapy is an alternative. Cure rates are 70–80% for toenail onychomycosis with a full systemic course.
Reservoir management is essential to prevent recurrence: decontaminate shoes (antifungal sprays or UV shoe sanitizers), treat co-existing tinea pedis in household contacts, use antifungal foot powder in at-risk situations (gym, pool). Breathable footwear and daily foot drying reduce recurrence rates.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Epidermophyton SCIT
SCIT has no evidence base for Epidermophyton floccosum. Antifungal therapy — the appropriate treatment — has established efficacy data for dermatophyte infections.
- Epidermophyton SCIT evidence0%No SCIT RCT identified for Epidermophyton — SCIT is not indicated for this organism (AAAAI/ACAAI Practice Parameter 2011)
- Oral terbinafine for toenail onychomycosis: mycologic cure76%Gupta AK et al., J Eur Acad Dermatol Venereol 2018 — terbinafine 250mg daily 12 weeks; N=multiple RCTs
- Topical terbinafine for tinea pedis: clinical cure at 6 weeks85%Villars VV, Jones TC. Clinical dermatology references — topical terbinafine 1% for interdigital tinea pedis
SCIT for Epidermophyton is not evidence-based and is not recommended in any guideline. Antifungal therapy achieves 75–85% mycologic cure for tinea infections. Patients with a positive Epidermophyton panel result should be directed to dermatologic care for active infection assessment and antifungal treatment rather than allergy immunotherapy evaluation.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Epidermophyton SCIT Side Effects
This section describes the side effects of antifungal treatment — the appropriate therapy for Epidermophyton — rather than SCIT side effects, which are not applicable.
Local reactions
2 documentedSystemic reactions
4 documentedAntifungal therapy for dermatophyte infection has a well-established safety profile. Oral terbinafine requires liver function monitoring for extended courses. All systemic antifungal prescriptions should include a drug interaction review. SCIT is not administered for Epidermophyton and has no applicable safety profile in this context.
SCIT vs Alternatives for Epidermophyton
For Epidermophyton floccosum, treatment alternatives are all antifungal — SCIT is not among the options because it is not indicated for this organism. Curex at-home testing surfaces dermatophyte sensitization and, when found, triggers an appropriate dermatology referral rather than an immunotherapy workup — ensuring patients get the right specialist for the right problem.
| Criterion | Topical azoles/terbinafineBest | Oral terbinafine | Oral itraconazole (pulse) | SCIT |
|---|---|---|---|---|
| Effectiveness | High for limited skin tinea (85%+) | High for onychomycosis (76%) | Moderate (similar to terbinafine) | Not indicated |
| Duration | 2–6 weeks | 6–12 weeks | 12–16 weeks total | Not applicable |
| Route | Topical application | Oral daily | Oral pulse dosing | Injection |
| Evidence level | Multiple RCTs | Multiple RCTs | Multiple RCTs | No evidence |
| Safety | Excellent local profile | Monitor liver function | Drug interactions | Not applicable |
| Recurrence prevention | Moderate — requires hygiene measures | 70% cure sustained 1+ year | Similar to terbinafine | Not applicable |
Topical azoles/terbinafineBest
Oral terbinafine
Oral itraconazole (pulse)
SCIT
Topical antifungal and oral terbinafine are the evidence-based treatments for Epidermophyton skin infections — not allergy shots. Curex at-home testing surfaces dermatophyte sensitization alongside inhalant allergens; for any confirmed inhalant allergies (dust mite, cat, pollen), Curex delivers subcutaneous immunotherapy as an at-home allergy shot at $129/month — a serum compounded under USP <797>, with the first dose and every dose change supervised live over Zoom, a prescribed epinephrine auto-injector confirmed on hand, and allergist-overseen escalation for those sensitizations separately.
What Epidermophyton SCIT Actually Costs
Antifungal medications for tinea infections are widely covered under standard pharmacy benefits. Dermatology consultation and fungal culture (CPT 87101) are typically covered for confirmed skin infections. SCIT billing codes are not applicable for Epidermophyton — allergy immunotherapy is not indicated for this organism.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
Flat monthly subscription — includes consult, prescription, and at-home dosing for sublingual immunotherapy.
See if you qualifyStop guessing about your epidermophyton allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Epidermophyton SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Epidermophyton floccosum appears on some comprehensive allergy panels as part of a fungal sensitization workup — particularly for patients with atopic dermatitis, chronic urticaria, or severe asthma where fungal IgE is being systematically evaluated. In atopic patients, IgE testing may detect sensitization to dermatophyte antigens from past skin infections (Epidermophyton raises IgE via its skin-contact antigen release). This sensitization does not mean you have inhaled allergy or that SCIT is appropriate — it typically reflects previous or current skin infection. The appropriate response to a positive Epidermophyton result is usually dermatologic evaluation for active tinea, not an allergy shot series.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.